176 related articles for article (PubMed ID: 34803400)
21. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
[TBL] [Abstract][Full Text] [Related]
22. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
[TBL] [Abstract][Full Text] [Related]
23. PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer.
Manson QF; Ter Hoeve ND; Buerger H; Moelans CB; van Diest PJ
Target Oncol; 2018 Dec; 13(6):769-777. PubMed ID: 30519815
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.
Jain E; Sharma S; Aggarwal A; Bhardwaj N; Dewan A; Kumar A; Jain D; Bhattacharya M; Saurav GK; Kini L; Mohanty SK
Pathol Res Pract; 2021 Dec; 228():153497. PubMed ID: 34053784
[TBL] [Abstract][Full Text] [Related]
25. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
Kim A; Lee SJ; Kim YK; Park WY; Park DY; Kim JY; Lee CH; Gong G; Huh GY; Choi KU
Sci Rep; 2017 Sep; 7(1):11671. PubMed ID: 28916815
[TBL] [Abstract][Full Text] [Related]
26. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
27. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
[TBL] [Abstract][Full Text] [Related]
28. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors.
Song JS; Kim D; Kwon JH; Kim HR; Choi CM; Jang SJ
Front Oncol; 2019; 9():1055. PubMed ID: 31681591
[No Abstract] [Full Text] [Related]
31. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
[TBL] [Abstract][Full Text] [Related]
32. Programmed Death-ligand 1 (PD-L1) Expression in Bladder Cancer and its Correlation with Tumor Grade, Stage, and Outcome.
Al Nabhani S; Al Harthy A; Al Riyami M; Al Sinawi S; Al Rashdi A; Al Husseni S; Kumar S
Oman Med J; 2022 Nov; 37(6):e441. PubMed ID: 36458243
[TBL] [Abstract][Full Text] [Related]
33. Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients.
Doğukan R; Uçak R; Doğukan FM; Tanık C; Çitgez B; Kabukcuoğlu F
Eur J Breast Health; 2019 Oct; 15(4):235-241. PubMed ID: 31620682
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological Features and Status of Programmed Death Ligand-1 (PD-L1) Expression in Lung Cancer: A Single Centre Study From North India.
Ganie F; Mehfooz N; Siraj F; Khan UH; Mantoo S; Dhar A; Mir MH; Jan RA; Shah S; Qadri SM
Cureus; 2023 Feb; 15(2):e35056. PubMed ID: 36942175
[TBL] [Abstract][Full Text] [Related]
35. Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters.
Li F; Ren Y; Wang Z
J Cancer Res Ther; 2018 Jan; 14(1):150-154. PubMed ID: 29516978
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
Sci Rep; 2019 Nov; 9(1):16662. PubMed ID: 31723167
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of programmed cell death ligand 1 expression in a contemporary cohort of penile squamous cell carcinoma and its correlation with clinicopathologic and survival parameters: A study of 134 patients.
Lobo A; Mishra SK; Jha S; Tiwari A; Kapoor R; Sharma S; Kaushal S; Kiranmai NS; Das MR; Peddinti KP; Sharma SK; Bhardwaj N; Arora S; Jain D; Jain E; Munjal G; Shinde S; Malik V; Singh H; Varshney J; Pradhan D; Dixit M; Pattnaik N; Sharma AK; Barapatre YR; Pradhan M; Satapathy K; Rath D; Jaiswal S; Das S; Khadenga C; Routa S; Baisakh MR; Tiwari R; Sampat NY; Chakrabarti I; Parwani AV; Mohanty SK
Am J Clin Pathol; 2024 Jan; 161(1):49-59. PubMed ID: 37639681
[TBL] [Abstract][Full Text] [Related]
39. Study of PD-L1 Expression with Association of Pathological Factors and Molecular Subtypes in Breast Carcinoma.
Gupta A; Chandra S; Chauhan N; Arora A
J Lab Physicians; 2022 Dec; 14(4):491-496. PubMed ID: 36531539
[No Abstract] [Full Text] [Related]
40. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer.
Zeng Y; Wang CL; Xian J; Ye Q; Qin X; Tan YW; Cao YD
Onco Targets Ther; 2019; 12():7193-7201. PubMed ID: 31564903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
